[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053645":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":33,"locations":41,"responsibleParty":133,"collaborators":10,"id":135,"slug":136,"hasResults":137,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":137,"sex":143,"minAge":10,"maxAge":10,"enrollmentInfo":144,"targetDuration":147,"studyType":148,"phases":10,"briefSummary":149,"conditions":150,"keywords":156,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":172},{"fullName":5,"class":6},"Boston Scientific Corporation","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Urinary Tract Procedure Cohort",null,"Subjects intend to undergo diagnostic and\u002For therapeutic urinary tract procedure with study device(s)",[13,14],"Device: Ureteroscope system","Device: Laser system",{"label":16,"type":10,"description":17,"interventionNames":18},"Benign Prostatic Hyperplasia Cohort","Subjects are at least 40 years of age diagnosed with BPH with lower urinary tract symptoms and intend to undergo BPH treatment with study device(s)",[14],[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DEVICE","Ureteroscope system","LithoVue™ Elite Single-Use Digital Flexible Ureteroscope System with intrarenal pressure monitoring",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"Laser system","Pulse™ 120H Holmium Laser System with MOSES™ 2.0 Technology",[16,9],[30],{"name":31,"affiliation":5,"role":32},"Gita Ghadimi, OD","STUDY_DIRECTOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":10,"email":38},"Winnie Chen","CONTACT","952-930-6000","SALTregistry@bsci.com",{"name":40,"role":36,"phone":37,"phoneExt":10,"email":10},"Curtis Blackwell",[42,63,80,100,116],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Mayo Clinic Phoenix","RECRUITING","Phoenix","Arizona","85054","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-112.07404,33.44838,{"lat":54,"lon":53},[57,60],{"name":58,"role":36,"phone":10,"phoneExt":10,"email":59},"Corbin Benson","benson.corbin@mayo.edu",{"name":61,"role":62,"phone":10,"phoneExt":10,"email":10},"Karen Stern, MD","PRINCIPAL_INVESTIGATOR",{"facility":64,"status":44,"city":65,"state":66,"zip":67,"country":48,"countryCode":49,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"University of Miami Hospital","Miami","Florida","33442",{"type":51,"coordinates":69},[70,71],-80.19366,25.77427,{"lat":71,"lon":70},[74,78],{"name":75,"role":36,"phone":76,"phoneExt":10,"email":77},"Elena Cortez","305-216-0394","ecortizas@med.miami.edu",{"name":79,"role":62,"phone":10,"phoneExt":10,"email":10},"Hemendra Shah, MD",{"facility":81,"status":44,"city":82,"state":66,"zip":83,"country":48,"countryCode":49,"cosmosGeoPoint":84,"geoPoint":88,"contacts":89},"University of South Florida","Tampa","33606",{"type":51,"coordinates":85},[86,87],-82.45843,27.94752,{"lat":87,"lon":86},[90,94,98],{"name":91,"role":36,"phone":92,"phoneExt":10,"email":93},"Ray De La Morena Quirch","813-844-8824","rdelamorena@tgh.org",{"name":95,"role":36,"phone":96,"phoneExt":10,"email":97},"Alexander Czachor","813-660-7065","aczachor@tgh.org",{"name":99,"role":62,"phone":10,"phoneExt":10,"email":10},"David Hernandez, MD",{"facility":101,"status":44,"city":102,"state":103,"zip":104,"country":48,"countryCode":49,"cosmosGeoPoint":105,"geoPoint":109,"contacts":110},"Indiana University Medical Center","Indianapolis","Indiana","46202",{"type":51,"coordinates":106},[107,108],-86.15804,39.76838,{"lat":108,"lon":107},[111,114],{"name":112,"role":36,"phone":10,"phoneExt":10,"email":113},"Stephanie Wofford","sdwillia@iu.edu",{"name":115,"role":62,"phone":10,"phoneExt":10,"email":10},"Macelino Rivera, MD",{"facility":117,"status":44,"city":118,"state":119,"zip":120,"country":48,"countryCode":49,"cosmosGeoPoint":121,"geoPoint":125,"contacts":126},"Duke University Medical Center","Durham","North Carolina","27710",{"type":51,"coordinates":122},[123,124],-78.89862,35.99403,{"lat":124,"lon":123},[127,131],{"name":128,"role":36,"phone":129,"phoneExt":10,"email":130},"Rebecca Schmidt","919-613-1178","rebecca.schmidt@duke.edu",{"name":132,"role":62,"phone":10,"phoneExt":10,"email":10},"Rohit Tejwani, MD",{"type":134,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100053645","stone-and-laser-therapies-post-market-study-salt-100053645",false,"NCT06982235","Stone and Laser Therapies Post-Market Study (SALT)","Stone and Laser Therapies Post-Market Study","SALT","Inclusion Criteria:\n\nFor urinary tract procedure cohort:\n\n1. Subject intends to undergo diagnostic and\u002For therapeutic urinary tract procedure with qualified BSC device(s)\n2. Subject is willing and able to complete all follow-up visits\n\nFor BPH cohort:\n\n1. Subject is ≥ 40 years of age\n2. Subject with a diagnosis of benign prostatic hyperplasia (BPH) with lower urinary tract symptoms\n3. Subject intends to undergo BPH treatment with qualified BSC device(s)\n4. Subject is willing and able to complete all follow-up visits\n\nExclusion Criteria:\n\nFor urinary tract procedure cohort:\n\n1. Subject requires simultaneous surgical treatment for BPH\n2. Unwilling or unable to provide consent\n3. Any other condition which, in the opinion of the investigator, precludes study participation (e.g., history of medical non-compliance, etc.)\n\nFor BPH cohort:\n\n1. Subject requires simultaneous upper urinary calculi lithotripsy procedure (not applicable to bladder calculi)\n2. Unwilling or unable to provide consent\n3. Any other condition which, in the opinion of the investigator, precludes study participation (e.g., history of medical non-compliance, etc.)","ALL",{"count":145,"type":146},238,"ESTIMATED","12 Months","OBSERVATIONAL","The objective of the SALT Study is to obtain post-market safety and device performance data for Boston Scientific's Stone and BPH study devices used during a diagnostic and\u002For therapeutic urinary tract procedure (e.g., transurethral or percutaneous access routes) or benign prostatic hyperplasia (BPH) treatment.",[151,152,153,154,155],"Benign Prostate Hypertrophy(BPH)","Renal Calculi","Ureteral Stones, Kidney Stones","Calculi, Urinary","Urinary Tract Procedure",[157,158,159,152,160,161,162,155],"BPH","Benign Prostatic Hyperplasia","Lithotripsy","Renal Calculus","Boston Scientific","Kidney Stone","2026-07-10",{"date":165,"type":166},"2026-07-13","ACTUAL",{"date":168,"type":166},"2025-06-30",{"date":170,"type":146},"2029-02",{"name":5,"class":6},5]